ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractBACKGROUND: ACTIBIND is an Aspergillus niger extracellular ribonuclease (T2-ribonuclease [RNase]) that possesses actin-binding activity. In plants, ACTIBIND inhibits the elongation and alters the orientation of pollen tubes by interfering with the intracellular actin network. The question rose whether ACTIBIND can also affect mammalian cancer development. METHODS: Cell colony formation was performed in human colon (HT-29, Caco-2, RSB), breast (ZR-75-1), and ovarian (2780) cancer cells in the presence or absence of 1 muM ACTIBIND. In HT-29 and ZR-75-1 cells, the effect of ACTIBIND on cell migration was studied by microscopic observations and by invasion assay through Matrigel. Tube formation was assessed in human umbilical vein endothelial cells (HUVEC) in the presence of angiogenin or basic fibroblast growth factor (bFGF) (1 microg/mL each) following overnight incubation with 1 or 10 microM ACTIBIND. In an athymic mouse xenograft model, HT-29 cells were injected subcutaneously, followed by subcutaneous (0.4-8 mg/mouse/injection) or intraperitoneal (0.001-1 mg/mouse/injection) injections of ACTIBIND. In a rat dimethylhydrazine (DMH)-colorectal carcinogenesis model, ACTIBIND was released directly into the colon via osmotic micropumps (250 microg/rat/day) or given orally via microcapsules (1.6 mg/rat/day). Aberrant crypt foci, tumors in the distal colon, and tumor blood vessels were examined. RESULTS: ACTIBIND had an anticlonogenic effect unrelated to its ribonuclease activity. It also inhibited angiogenin-induced HUVEC tube formation in a dose-responsive manner. ACTIBIND was found to bind actin in vitro. It also bound to cancer cell surfaces, leading to disruption of the internal actin network and inhibiting cell motility and invasiveness through Matrigel-coated filters. In mice, ACTIBIND inhibited HT-29 xenograft tumor development, given either as a subcutaneous or intraperitoneal treatment. In rats, ACTIBIND exerted preventive and therapeutic effects on developing colonic tumors induced by DMH. It also reduced the degree of tumor observation. CONCLUSIONS: This study indicated that ACTIBIND is an effective antiangiogenic and anticarcinogenic factor.
CitationCancer 2006, 106 (10):2295-2308
DescriptionKEYWORDS CLASSIFICATION: Agriculture;Angiogenesis Inhibitors;Animals;Anticarcinogenic Agents;Aspergillus niger;blood;Biopsy,Needle;Breast Neoplasms;cytology;Colorectal Neoplasms;dietary modulation of cancer & cancer biomarkers;drug effects;drug therapy;Disease Models,Animal;Endoribonucleases;Female;Food;Humans;Immunohistochemistry;Israel;lifestyle modulation of cancer & cancer biomarkers;Male;Mice;Mice,Nude;Neoplasm Transplantation;Neovascularization,Pathologic;pathology;pharmacology;prevention & control;Probability;Rats;Reference Values;Ribonucleases;Risk Factors;Sensitivity and Specificity;Transplantation,Heterologous;Tumor Cells,Cultured.
- A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization.
- Authors: Smirnoff P, Roiz L, Angelkovitch B, Schwartz B, Shoseyov O
- Issue date: 2006 Dec 15
- The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
- Authors: Ruggeri BA, Robinson C, Angeles T, Wilkinson J 4th, Clapper ML
- Issue date: 2002 Jan
- [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
- Authors: Wang YD, Hu Y, Zhang L, Huang J, Sun CY
- Issue date: 2007 Oct
- ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis.
- Authors: Schwartz B, Shoseyov O, Melnikova VO, McCarty M, Leslie M, Roiz L, Smirnoff P, Hu GF, Lev D, Bar-Eli M
- Issue date: 2007 Jun 1
- The 1.8 Å crystal structure of ACTIBIND suggests a mode of action for T2 ribonucleases as antitumorigenic agents.
- Authors: de Leeuw M, González A, Lanir A, Roiz L, Smirnoff P, Schwartz B, Shoseyov O, Almog O
- Issue date: 2012 Feb 9